Last updated: July 2026
How Effective Is PrEP, Really?
"99% effective" gets repeated everywhere — but 99% under what conditions, and what about the other 1%? Here's what the trials and a decade of real-world use actually show, including the honest caveats.
The short version
- Daily oral PrEP: ~99% risk reduction for sexual exposure at full adherence.
- Effectiveness tracks adherence — it falls off meaningfully below ~4 doses/week (and stricter for vaginal exposure).
- Injectable PrEP outperformed daily pills in trials, driven by adherence.
- Documented breakthrough infections on truly adherent PrEP are vanishingly rare — case-report rare.
Where the numbers come from
The pivotal trials (iPrEx and partners studies for oral TDF-FTC; DISCOVER for Descovy; HPTN 083/084 for injectable cabotegravir) plus massive real-world cohorts like San Francisco's and Australia's PrEP rollouts. In the trials, protection correlated tightly with drug levels in blood: participants with levels reflecting daily dosing had near-total protection, while "trial average" effectiveness (44% in iPrEx) reflected the many participants who simply didn't take the pills. The gap between 44% and 99% is not pharmacology — it's adherence.
The adherence curve, quantified
| Oral doses per week | Estimated protection (anal exposure) |
|---|---|
| 7 (daily) | ~99% |
| 4 | ~96% |
| 2 | ~76% |
| 0 | 0% |
Two important asterisks. First, these estimates come from men who have sex with men; for receptive vaginal exposure, tissue drug levels build slower and lower, so daily dosing matters more — the forgiveness in the table doesn't transfer. Second, this forgiving curve is exactly what makes 2-1-1 dosing viable for MSM and not for others.
The rare breakthroughs
A handful of infections despite documented adherence have been reported worldwide, essentially all involving transmitted virus already resistant to the PrEP drugs. They number in the dozens against millions of person-years of use. PrEP's real-world failure mode isn't the drug failing — it's doses not taken, or PrEP started during an undetected early infection (why baseline and quarterly testing is non-negotiable).
What this means for your choice
If you'll take a daily pill reliably, oral PrEP gives you ~99%. If you know yourself to be a sporadic pill-taker, that honesty is valuable — it points you toward the injection, which removed the adherence variable so effectively it beat daily pills in head-to-head trials. Either way, combining PrEP with DoxyPEP extends protection across the STIs PrEP doesn't touch. Talk through the fit at a telehealth visit.